Journal of Neurology, Neurosurgery and Psychiatry

is a leading international journal publishing the latest research and reviews on all areas of neurological sciences.

Impact Factor: 8.8
Citescore: 15.7
All metrics >>

Journal of Neurology, Neurosurgery and Psychiatry (JNNP)'s ambition is to publish the most ground-breaking and cutting-edge research from around the world. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson's disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen interest in the Gordian knots that present themselves in the field, such as ALS. With early online publication, regular podcasts and an immense archive collection, JNNP is a trail-blazer and not a follower.

Subscribers to JNNP also have access to Practical Neurology and the Journal of NeuroInterventional Surgery.

JNNP has a fully open access companion journal, BMJ Neurology Open, publishing research in all areas of clinical neurology and neuroscience.

JNNP publishes regular podcasts discussing highlights from its issues. Subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

Editor in Chief: Dr Karen Furie, Warren Alpert Medical School of Brown University
Editorial Board

Current Issue

Authors

JNNP accepts submissions of a wide range of article types, including review articles and original research.

The Author Information section provides specific article requirements to help you turn your research into an article suitable for JNNP.

Information is also provided on editorial policies and open access.

Author information Submit a paper

Latest Articles

Editorial commentaries:

C5 complement inhibition and FcRn modulation in generalized myasthenia gravis. Fast-acting but short-lived therapies the use of which should prompt assertive escalation of conventional treatments

24 March 2025

Neuromuscular:

C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis

24 March 2025

Neuromuscular:

Efgartigimod efficacy and safety in refractory myasthenia gravis: UKs first real-world experience

24 March 2025

Neuromuscular:

Multiple metal exposures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: a case-control study

24 March 2025

Neuromuscular:

Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management

24 March 2025

Most Read Articles

General neurology:

Understanding the pathophysiology of idiopathic intracranial hypertension (IIH): a review of recent developments

13 March 2024

Neuromuscular:

Novel therapies in CIDP

16 December 2024

Neuropsychiatry:

Pain and functional neurological disorder: a systematic review and meta-analysis

16 August 2024

Neuromuscular:

Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies

16 August 2024

Neuropsychiatry:

NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence

17 June 2024

Featured Video

Implications for driving based on the risk of seizures after ischaemic stroke

30 April 2024

Conclusion: Personalised prognostic models, such as SeLECT2.0, may offer better guidance for poststroke driving decisions than generic SFIs. Our findings provide practical tools, including a smartphone-based or web-based application, to assess seizure risks and determine appropriate SFIs for safe driving.

Find out more